Arcus Biosciences Inc
NYSE:RCUS
Arcus Biosciences Inc
NYSE:RCUS
Price:
24.42
USD
-0.57%
Market Closed
Market Cap:
$3B
Balance Sheet
Balance Sheet Decomposition
Arcus Biosciences Inc
Arcus Biosciences Inc
Balance Sheet Decomposition is not available for
Arcus Biosciences Inc
Arcus Biosciences Inc
Balance Sheet
Arcus Biosciences Inc
Arcus Biosciences Inc
Currency: USD
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
65
|
98
|
71
|
58
|
173
|
148
|
206
|
127
|
150
|
222
|
|
| Cash Equivalents |
65
|
98
|
71
|
58
|
173
|
148
|
206
|
127
|
150
|
222
|
|
| Short-Term Investments |
34
|
77
|
186
|
130
|
555
|
351
|
803
|
632
|
828
|
759
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
2
|
747
|
39
|
42
|
25
|
16
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
2
|
747
|
39
|
42
|
25
|
16
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
1
|
2
|
4
|
6
|
16
|
19
|
30
|
13
|
10
|
|
| Total Current Assets |
100
|
177
|
259
|
193
|
736
|
1 262
|
1 067
|
831
|
1 016
|
1 007
|
|
| PP&E Net |
9
|
11
|
11
|
9
|
24
|
137
|
135
|
143
|
112
|
98
|
|
| PP&E Gross |
9
|
11
|
11
|
9
|
24
|
137
|
135
|
143
|
112
|
98
|
|
| Accumulated Depreciation |
1
|
4
|
8
|
11
|
14
|
18
|
23
|
31
|
41
|
50
|
|
| Long-Term Investments |
1
|
1
|
4
|
0
|
6
|
182
|
129
|
107
|
14
|
29
|
|
| Other Long-Term Assets |
0
|
2
|
1
|
1
|
6
|
11
|
14
|
14
|
8
|
5
|
|
| Total Assets |
110
N/A
|
191
+74%
|
275
+44%
|
203
-26%
|
772
+280%
|
1 592
+106%
|
1 345
-16%
|
1 095
-19%
|
1 150
+5%
|
1 139
-1%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
4
|
4
|
3
|
5
|
16
|
10
|
20
|
17
|
18
|
42
|
|
| Accrued Liabilities |
1
|
3
|
6
|
10
|
31
|
52
|
76
|
76
|
122
|
153
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
1
|
6
|
8
|
9
|
75
|
104
|
97
|
91
|
86
|
36
|
|
| Total Current Liabilities |
6
|
13
|
17
|
23
|
122
|
166
|
193
|
184
|
226
|
231
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
48
|
99
|
|
| Other Liabilities |
5
|
24
|
23
|
17
|
148
|
584
|
495
|
449
|
391
|
178
|
|
| Total Liabilities |
10
N/A
|
37
+259%
|
40
+9%
|
39
-2%
|
270
+587%
|
750
+178%
|
688
-8%
|
633
-8%
|
665
+5%
|
508
-24%
|
|
| Equity | |||||||||||
| Common Stock |
120
|
226
|
0
|
0
|
0
|
0
|
1 206
|
1 311
|
1 617
|
2 116
|
|
| Retained Earnings |
20
|
73
|
123
|
205
|
328
|
275
|
542
|
849
|
1 132
|
1 485
|
|
| Additional Paid In Capital |
0
|
1
|
358
|
369
|
830
|
1 118
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
1
|
7
|
0
|
0
|
0
|
|
| Total Equity |
100
N/A
|
154
+55%
|
235
+53%
|
164
-30%
|
502
+207%
|
842
+68%
|
657
-22%
|
462
-30%
|
485
+5%
|
631
+30%
|
|
| Total Liabilities & Equity |
110
N/A
|
191
+74%
|
275
+44%
|
203
-26%
|
772
+280%
|
1 592
+106%
|
1 345
-16%
|
1 095
-19%
|
1 150
+5%
|
1 139
-1%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
42
|
42
|
45
|
46
|
65
|
71
|
73
|
76
|
92
|
125
|
|
Switch to:
Switch to:
See Also
Discover More
